Skip to content
lifestyle.lincolnlabs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
R1 Therapeutics
R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026
October 15, 2026
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
September 30, 2026
R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
July 21, 2026
R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
June 30, 2026
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
March 17, 2026